USFDA issues warning letter to Ipca Labs for 3 plants

It has been another tough week for some of India's troubled drugmakers.

The company, which had already suspended exports of products, mainly active pharma ingredients (APIs) and drug formulations last following negative observations in inspections conducted by the U.S. drug regulator at these factories and a subsequent import alert on certain products.

Drug firm Ipca Laboratories has received a warning letter from the USA health regulator for three facilities on which the regulator had earlier imposed an import ban for not adhering to the good manufacturing norms.

A January preapproval inspection at a Wockhardt plant in Shendra determined that the plant is not yet ready for prime time. The FDA issued a Form 483 with 9 observations, many of them to do with data integrity, according to The Economic Times. The company claimed none of the observations were "serious". "Therefore, since July 2014 the company has not shipped any APls or formulations to USA market except the products which are exempted from import alert", Ipca said in its notice. Before the bans, Wockhardt derived more than half of its revenues from its USA sales, but by previous year that was down to about 25% and falling.

The letter concerns the company's Ratlam and SEZ Indore plants in central India, and the Piparia facility in western India, IPCA said in a statement.

Apparently, it is not the only IPCA that is facing the wrath from the FDA. The FDA usually posts such letters on its website a week after issuing them to manufacturers, who need to respond to the agency within 15 days with a plan on how they would work on fixing the issues.

"Since the inspection, the company has regularly communicated with US FDA with periodic updates on remedial measures undertaken and it is fully committed in resolving this issue at the earliest", it added.

Source: http://leadercall.com/2016/02/usfda-issues-warning-letter-to-ipca-labs-for-3-plants/

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

PHYTOCON 2018 - Commercialization of medicinal plant products: Lab techniques to trade_14 April 2018